Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

“These findings expand upon the growing body of literature raising concerns regarding the potential ocular safety of systemic GLP-1 RA use in patients with diabetes,” researchers ...

MET-097i, our most advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA that we are ... of action, or "MoA" to Novo's drug candidate ...

Annual prevalence of GLP-1 RA use among US adults without diabetes increased from 0.1% in 2018-2021 to 0.4% in 2022, with an estimated 854,728 adults without diabetes taking these medications.

no use impacts the odds for outcomes following transplantation. Of the total cohort, 34 had GLP-1 RA use in the outlined time frame (mean time to initiation, 318 days), with 23 patients prescribed ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ablation, according to a large Veterans Affairs database. New initiators ...

There were 396,963 eligible patients with T2D, of whom 33,858 were included in the GLP-1 RA versus the other glucose-lowering drug (GLD) cohort; 34,185 in the SGLT2i versus the other GLD cohort ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are gaining popularity as a weight loss solution due to their effectiveness in managing appetite and blood sugar levels. We spoke with Dr ...

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor ... short amount of 12-weeks already proved that its GLP-1 RA MET-097i already attained a mean placebo adjusted ...